Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus

Summary

Approximately 225 patients meeting study entry requirements will be enrolled and randomized (2:1, active versus placebo superimposed on background treatment) to R788 or placebo. Patients will be followed for efficacy and safety parameters for 6 months. The investigator should taper corticosteroids if clinically warranted.

Timeline

Start

2008-11

Primary completion

2009-11

Completion

2010-03

Drugs

Indications